Literature DB >> 11980959

Shiga toxin-producing Escherichia coli infection and antibodies against Stx2 and Stx1 in household contacts of children with enteropathic hemolytic-uremic syndrome.

Kerstin Ludwig1, Volkan Sarkim, Martin Bitzan, Mohamed A Karmali, Christoph Bobrowski, Hans Ruder, Rainer Laufs, Ingo Sobottka, Martin Petric, Helge Karch, Dirk E Müller-Wiefel.   

Abstract

Ninety-five household contacts (aged 2 months to 73 years) of patients with enteropathic hemolytic-uremic syndrome (HUS) were investigated for the presence of immunoglobulin (Ig) G antibodies to Shiga toxins Stx2 and Stx1 by Western blot assay. Thirty-one percent of the household contacts and 19% of 327 controls had anti-Stx2 IgG (heavy and light chain [H + L]), 5 and 8%, respectively, had anti-Stx1 IgG (H + L), and 3 and 2%, respectively, had both anti-Stx2 and anti-Stx1 IgG (H + L). The incidence of infections with Stx-producing Escherichia coli (STEC) was determined based on the following diagnostic criteria: STEC isolation, detection of stx gene sequences, free fecal Stx in stool filtrates, and serum IgM antibodies against E. coli O157 lipopolysaccharide. Evidence of STEC infection was observed in 25 household contacts, of whom 18 (72%) were asymptomatic and represented a potential source of infection. Six of 13 (46%) household contacts with Stx2-producing E. coli O157:H7 in stool culture developed anti-Stx2 IgG (H + L), compared to 71% of Stx2-associated HUS cases. In individuals showing anti-Stx2 IgG (H + L), the antibody response was directed against the B subunit in 69% of household contacts and 71% of controls, in contrast to 28% of HUS patients. In this investigation controls had a significant increase of the median of IgM antibodies to O157 lipopolysaccharide (LPS) with age, up to the fifth decade. The lack of disease in household contacts with B subunit-specific antibodies, as well as the significantly higher median of anti-O157 LPS IgM antibodies in controls beyond 4.9 years of age, suggests a protective role for anti-Stx and anti-O157 LPS antibodies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11980959      PMCID: PMC130915          DOI: 10.1128/JCM.40.5.1773-1782.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  53 in total

1.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

2.  Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities.

Authors:  N A Strockbine; L R Marques; J W Newland; H W Smith; R K Holmes; A D O'Brien
Journal:  Infect Immun       Date:  1986-07       Impact factor: 3.441

3.  Ultrasensitive stain for proteins in polyacrylamide gels shows regional variation in cerebrospinal fluid proteins.

Authors:  C R Merril; D Goldman; S A Sedman; M H Ebert
Journal:  Science       Date:  1981-03-27       Impact factor: 47.728

Review 4.  Hemolytic-uremic syndrome. Current concepts and management.

Authors:  J S Fong; J P de Chadarevian; B S Kaplan
Journal:  Pediatr Clin North Am       Date:  1982-08       Impact factor: 3.278

5.  Cloning and expression of the genes specifying Shiga-like toxin production in Escherichia coli H19.

Authors:  A Huang; S de Grandis; J Friesen; M Karmali; M Petric; R Congi; J L Brunton
Journal:  J Bacteriol       Date:  1986-05       Impact factor: 3.490

6.  Mucosal and systemic antibody responses to the lipopolysaccharide of Escherichia coli O157 in health and disease.

Authors:  Carol G Currie; Kirsten McCALLUM; Ian R Poxton
Journal:  J Med Microbiol       Date:  2001-04       Impact factor: 2.472

7.  Hemolytic uremic syndrome and diarrhea associated with Escherichia coli O157:H7 in a day care center.

Authors:  J S Spika; J E Parsons; D Nordenberg; J G Wells; R A Gunn; P A Blake
Journal:  J Pediatr       Date:  1986-08       Impact factor: 4.406

8.  Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools.

Authors:  M A Karmali; B T Steele; M Petric; C Lim
Journal:  Lancet       Date:  1983-03-19       Impact factor: 79.321

9.  Hemorrhagic colitis associated with a rare Escherichia coli serotype.

Authors:  L W Riley; R S Remis; S D Helgerson; H B McGee; J G Wells; B R Davis; R J Hebert; E S Olcott; L M Johnson; N T Hargrett; P A Blake; M L Cohen
Journal:  N Engl J Med       Date:  1983-03-24       Impact factor: 91.245

10.  The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli.

Authors:  M A Karmali; M Petric; C Lim; P C Fleming; G S Arbus; H Lior
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

View more
  21 in total

1.  Evaluation of the anti-terminator Q933 gene as a marker for Escherichia coli O157:H7 with high Shiga toxin production.

Authors:  Aqeel Ahmad; Ludek Zurek
Journal:  Curr Microbiol       Date:  2006-09-12       Impact factor: 2.188

2.  Convergent synthesis of the pentasaccharide repeating unit of the O-antigenic polysaccharide of enterohaemorrhagic Escherichia coli O113.

Authors:  Abhishek Santra; Anup Kumar Misra
Journal:  Glycoconj J       Date:  2012-05-05       Impact factor: 2.916

3.  Long-Term Survival and Thermal Death Kinetics of Enterohemorrhagic Escherichia coli Serogroups O26, O103, O111, and O157 in Wheat Flour.

Authors:  Fereidoun Forghani; Meghan den Bakker; Alexandra N Futral; Francisco Diez-Gonzalez
Journal:  Appl Environ Microbiol       Date:  2018-06-18       Impact factor: 4.792

4.  Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers.

Authors:  Thomas C Dowling; Pierre A Chavaillaz; David G Young; Angela Melton-Celsa; Alison O'Brien; Claire Thuning-Roberson; Robert Edelman; Carol O Tacket
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

5.  Prevalence of enteric bacteria that inhibit growth of enterohaemorrhagic Escherichia coli O157 in humans.

Authors:  H Toshima; M Hachio; Y Ikemoto; J Ogasawara; A Hase; K Takahashi; H Masaki; Y Nishikawa
Journal:  Epidemiol Infect       Date:  2006-06-02       Impact factor: 2.451

6.  Hemolytic uremic syndrome associated with Entamoeba histolytica intestinal infection.

Authors:  Felipe Cavagnaro; Carla Guzmán; Paul Harris
Journal:  Pediatr Nephrol       Date:  2005-10-13       Impact factor: 3.714

7.  Contamination Scenario Matters when Using Viral and Bacterial Human-Associated Genetic Markers as Indicators of a Health Risk in Untreated Sewage-Impacted Recreational Waters.

Authors:  Mary E Schoen; Alexandria B Boehm; Jeffrey Soller; Orin C Shanks
Journal:  Environ Sci Technol       Date:  2020-10-08       Impact factor: 9.028

8.  Shiga toxin-producing Escherichia coli in household members of children with hemolytic uremic syndrome.

Authors:  Laura Fernanda Alconcher; Marta Rivas; Lucas Ivan Lucarelli; Jimena Galavotti; Mabel Rizzo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-11-28       Impact factor: 3.267

9.  Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease.

Authors:  Tom G Obrig
Journal:  Toxins (Basel)       Date:  2010-12-02       Impact factor: 4.546

10.  Eliglustat prevents Shiga toxin 2 cytotoxic effects in human renal tubular epithelial cells.

Authors:  Daiana S Sánchez; Lilian K Fischer Sigel; Alejandro Balestracci; Cristina Ibarra; María M Amaral; Claudia Silberstein
Journal:  Pediatr Res       Date:  2021-06-21       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.